Last update: Aug. 18, 2017
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the intestinal hormone GLP-1 that is activated upon eating (EMA 2016, Scheen 2011).
Very low risk of hypoglycemia.
Recommended dose: one to two doses daily.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (EMA 2016, Scheen 2011) - low molecular weight and low percentage of binding to plasma proteins - makes it likely that significant amounts will pass into breast milk.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM